Clinical comparative study of two kinds of drugs in the treatment of preterm infants with primary apnea
10.3969/j.issn.1005-1678.2017.09.143
- VernacularTitle:两种药物治疗原发性呼吸暂停早产儿临床对比研究
- Author:
Liuqing JI
- Keywords:
Aminophylline;
Caffeine citrate;
primary apnea;
preterm infants;
clinical effects;
safety
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(9):322-324
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effects and safety of Aminophylline and Caffeine citrate in the treatment of preterm infants with primary apnea. Methods 130 preterm infants with primary apnea were chosen and randomly divided into both group including the Aminophylline group (65 children) with aminophylline and the Caffeine citrate group (65 children) with Caffeine citrate on the basis of conventional intervention; and the total oxygen inhalation time, mechanical ventilation time, hospitalization time, the complications incidence with follow-up and the levels of development quotient for short-term of both groups were compared. Results The total oxygen inhalation time, the mechanical ventilation time and the hospitalization time of Caffeine citrate group were significantly shorter than aminophylline group(P<0.05). The incidence of PDA, BPD and ROP of Caffeine citrate group were significantly lower than aminophylline group(P<0.05). There was no significant difference in the incidence of intracranial hemorrhage, PVL and NEC between two groups. The development quotient levels in 24 weeks and 48 weeks after treatment of Caffeine citrate group were significantly higher than aminophylline group(P<0.05). Conclusion Compared with Aminophylline, Caffeine citrate on the basis of conventional intervention in the treatment of preterm infants with primary apnea could efficiently shorten the oxygen inhalation time, the mechanical ventilation time and clinical disease course, reduce the related complications risk and be helpful to promote the intellectual development.
